322 related articles for article (PubMed ID: 34321321)
21. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
22. Angiopoietin-2-Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma.
Park HR; Shiva A; Cummings P; Kim S; Kim S; Lee E; Leong A; Chowdhury S; Shawber C; Carvajal R; Thurston G; An JY; Lund AW; Yang HW; Kim M
Cancer Res; 2023 Jun; 83(12):1968-1983. PubMed ID: 37093870
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
24. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment.
Li Z; Zhang XJ; Sun CY; Fei H; Li ZF; Zhao DB
World J Clin Cases; 2023 Feb; 11(4):738-755. PubMed ID: 36818626
[TBL] [Abstract][Full Text] [Related]
25. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.
Wu B; Fu L; Guo X; Hu H; Li Y; Shi Y; Zhang Y; Han S; Lv C; Tian Y
Front Immunol; 2023; 14():984816. PubMed ID: 36761750
[TBL] [Abstract][Full Text] [Related]
26. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Finisguerra V; Dvorakova T; Formenti M; Van Meerbeeck P; Mignion L; Gallez B; Van den Eynde BJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147018
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
28. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
29. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
30. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
31. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration.
Barbera S; Nardi F; Elia I; Realini G; Lugano R; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
Cell Commun Signal; 2019 May; 17(1):55. PubMed ID: 31138217
[TBL] [Abstract][Full Text] [Related]
32. Role of CD93 in Health and Disease.
Tossetta G; Piani F; Borghi C; Marzioni D
Cells; 2023 Jul; 12(13):. PubMed ID: 37443812
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
34. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
35. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
[TBL] [Abstract][Full Text] [Related]
36. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
[TBL] [Abstract][Full Text] [Related]
37. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy.
Qian C; Yang C; Tang Y; Zheng W; Zhou Y; Zhang S; Song M; Cheng P; Wei Z; Zhong C; Wan L; Wang A; Zhao Y; Lu Y
Pharmacol Res; 2022 Aug; 182():106333. PubMed ID: 35779815
[TBL] [Abstract][Full Text] [Related]
39. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
Sen T; Della Corte CM; Milutinovic S; Cardnell RJ; Diao L; Ramkumar K; Gay CM; Stewart CA; Fan Y; Shen L; Hansen RJ; Strouse B; Hedrick MP; Hassig CA; Heymach JV; Wang J; Byers LA
J Thorac Oncol; 2019 Dec; 14(12):2152-2163. PubMed ID: 31470128
[TBL] [Abstract][Full Text] [Related]
40. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
